A Phase 3 interventional study of Placebo and Azilsartan medoxomil in Hypertension and Diabetes, sponsored by Takeda. Terminated at 68 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.
Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 18th largest by enrollment, is the only one that started in 2012, is one of 17 in phase 3, and was the 18th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2012.
This study's enrollment of 105 is close to the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 566 across the 21 interventional studies. Of the 20 that completed or were terminated, 20 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
44 studies in Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 44 studies in Hypertension by Takeda, this one is the 25th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2012, is one of 25 in phase 3, and was the 26th registered.
Takeda’s Hypertension studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing azilsartan medoxomil in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 44 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.
The study included a Screening Period of up to 4 weeks, which coincided with a 2-week single-blind, placebo Run-in Period, a 24 week Treatment Period, and a 2-week Follow-up Period. The duration of the study was approximately 30 weeks. The planned number of participants (n=450) was not reached; actual enrollment consisted of 105 particpants. Due to low enrollment this study was terminated early by Takeda.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
Drug: Placebo
Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
Drug: Azilsartan medoxomil
Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
Drug: Azilsartan medoxomil
Also known as: TAK-491
Also known as: TAK-491
Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure
The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 8
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.
Time frame: Baseline and Week 24
Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure
The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 8
Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8
Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8
Percentage of Participants Requiring Rescue Glycemic Therapy
Percentage of participants requiring rescue glycemic therapy during study.
Time frame: 24 Weeks
Time to First Glycemic Rescue
The time to the first instance of participants requiring glycemic rescue during study.
Time frame: 24 Weeks
Change From Baseline in HbA1c
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.
Time frame: Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20
Change From Baseline in Fasting Plasma Glucose
The change between the fasting plasma glucose value collected at each week indicated relative to baseline.
Time frame: Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24
Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)
The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT
The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT
The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT
The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT
The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT
The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
Time frame: Baseline and Weeks 6 and 24
Participants took part in the study at 41 investigative sites in the United States from 09 January 2012 to 30 May 2013.
| Milestone | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Started | 35 | 35 | 35 |
| Completed | 29 | 30 | 25 |
| Not completed | 6 | 5 | 10 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Major protocol deviation | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 |
| Withdrew: Voluntary withdrawal | 2 | 1 | 6 |
| Withdrew: Principal investigator discretion | 0 | 1 | 1 |
| Withdrew: Other | 2 | 0 | 0 |
The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure | -3.1 ± 2.71 | -10.2 ± 2.69 | -13.6 ± 2.70 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.
| percentage glycosylated hemoglobin | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | 0.12 ± 0.174 | -0.19 ± 0.174 | 0.07 ± 0.179 |
The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure | -0.8 ± 1.36 | -5.4 ± 1.37 | -5.8 ± 1.37 |
The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -1.6 ± 2.25 | -8.3 ± 2.15 | -11.3 ± 2.31 |
The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -1.0 ± 1.28 | -4.7 ± 1.22 | -7.2 ± 1.31 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -2.0 ± 2.23 | -9.0 ± 2.13 | -11.7 ± 2.28 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -1.4 ± 1.25 | -5.1 ± 1.20 | -7.5 ± 1.28 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | 0.4 ± 2.68 | -6.2 ± 2.57 | -10.9 ± 2.76 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | 0.6 ± 1.65 | -3.2 ± 1.58 | -7.2 ± 1.69 |
The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | -2.7 ± 2.40 | -8.6 ± 2.29 | -12.3 ± 2.45 |
The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | -1.9 ± 1.37 | -4.7 ± 1.31 | -8.2 ± 1.40 |
The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | 2.3 ± 2.80 | -7.6 ± 2.67 | -7.9 ± 2.87 |
The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mm Hg | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | 0.2 ± 1.63 | -6.8 ± 1.57 | -4.0 ± 1.66 |
Percentage of participants requiring rescue glycemic therapy during study.
| percentage of participants | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Percentage of Participants Requiring Rescue Glycemic Therapy | 25.7 | 25.7 | 25.7 |
The time to the first instance of participants requiring glycemic rescue during study.
| Days | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Time to First Glycemic Rescue | NA (21.57 to NA) | NA (22.57 to NA) | NA (17.14 to NA) |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.
| percentage glycosylated hemoglobin | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 2 (n=34, 35, 32) | -0.01 ± 0.072 | 0.05 ± 0.071 | -0.06 ± 0.074 |
| Week 4 (n=35, 35, 33) | -0.02 ± 0.093 | -0.02 ± 0.093 | 0.29 ± 0.096 |
| Week 6 (n=35, 35, 33) | 0.06 ± 0.123 | -0.02 ± 0.123 | 0.24 ± 0.127 |
| Week 8 (n=35, 35, 33) | 0.05 ± 0.137 | -0.03 ± 0.138 | 0.23 ± 0.141 |
| Week 12 (n=35, 35, 33) | 0.00 ± 0.171 | -0.05 ± 0.171 | 0.29 ± 0.176 |
| Week 16 (n=35, 35, 33) | 0.09 ± 0.171 | -0.06 ± 0.171 | 0.16 ± 0.176 |
| Week 20 (n=35, 35, 33) | 0.14 ± 0.167 | -0.13 ± 0.168 | 0.09 ± 0.172 |
The change between the fasting plasma glucose value collected at each week indicated relative to baseline.
| mmol/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 2 (n=34, 35, 34) | 0.16 ± 0.435 | 0.64 ± 0.429 | 1.03 ± 0.435 |
| Week 4 (n=35, 35, 34) | 0.96 ± 0.464 | 0.45 ± 0.464 | 0.81 ± 0.470 |
| Week 6 (n=35, 35, 34) | 0.71 ± 0.445 | 0.28 ± 0.445 | 0.81 ± 0.451 |
| Week 8 (n=35, 35, 34) | 0.39 ± 0.368 | 0.34 ± 0.368 | 0.96 ± 0.373 |
| Week 12 (n=35, 35, 34) | 0.76 ± 0.417 | 0.09 ± 0.417 | 0.94 ± 0.423 |
| Week 16 (n=35, 35, 34) | 0.36 ± 0.379 | 0.17 ± 0.379 | 0.49 ± 0.384 |
| Week 20 (n=35, 35, 34) | 0.94 ± 0.438 | 0.01 ± 0.438 | 0.86 ± 0.444 |
| Week 24 (n=35, 35, 34) | 0.76 ± 0.459 | -0.15 ± 0.459 | 0.48 ± 0.465 |
The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| mmol/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=30, 30, 29) | 1.01 ± 0.555 | -0.46 ± 0.556 | -0.09 ± 0.565 |
| Week 24 (n=25, 26, 19) | -0.44 ± 0.824 | -1.66 ± 0.811 | -3.94 ± 0.949 |
The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| mmol*hours/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=28, 29, 29) | 1.60 ± 1.159 | -1.01 ± 1.148 | 1.04 ± 1.140 |
| Week 24 (n=23, 24, 19) | -1.97 ± 1.339 | -1.13 ± 1.308 | -5.52 ± 1.471 |
The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| pmol*hours/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=28, 31, 28) | 64.4 ± 74.80 | -26.1 ± 71.42 | 19.5 ± 74.78 |
| Week 24 (n=21, 25, 19) | -63.3 ± 162.81 | 80.1 ± 149.88 | 477.0 ± 169.22 |
The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| nmol*hours/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=28, 31, 28) | 0.051 ± 0.1779 | -0.091 ± 0.1696 | -0.138 ± 0.1780 |
| Week 24 (n=21, 25, 19) | -0.449 ± 0.2323 | 0.182 ± 0.2138 | 0.155 ± 0.2444 |
The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| pmol*hr/mmol | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=27, 29, 28) | 4.86 ± 5.777 | 1.73 ± 5.578 | -0.75 ± 5.663 |
| Week 24 (n=20, 23, 19) | -5.36 ± 14.823 | 1.05 ± 13.883 | 52.68 ± 14.976 |
The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.
| ng*hours/L | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Week 6 (n=27, 27, 27) | -5.8 ± 9.34 | 27.1 ± 9.39 | 0.2 ± 9.32 |
| Week 24 (n=22, 23, 19) | 2.7 ± 8.51 | 12.0 ± 8.45 | 1.0 ± 9.34 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug, for up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QD | — | 0/35 (0%) | 10/35 (28.6%) |
| Azilsartan Medoxomil 40 mg QD | — | 1/35 (2.9%) | 10/35 (28.6%) |
| Azilsartan Medoxomil 80 mg QD | — | 0/35 (0%) | 8/35 (22.9%) |
| Event | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/35 | 1/35 | 0/35 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/35 | 1/35 | 0/35 |
| Event | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 3/35 | 4/35 | 3/35 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/35 | 2/35 | 2/35 |
| DiarrhoeaGastrointestinal disorders | 2/35 | 1/35 | 2/35 |
| Upper respiratory tract infectionInfections and infestations | 2/35 | 1/35 | 2/35 |
| ConstipationGastrointestinal disorders | 2/35 | 1/35 | 1/35 |
| CholelithiasisHepatobiliary disorders | 0/35 | 2/35 | 0/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/35 | 2/35 | 0/35 |
| ProteinuriaRenal and urinary disorders | 2/35 | 0/35 | 0/35 |
Randomized Set includes all enrolled participants who were randomized via the Interactive Voice/Web Response System.
| Age, Continuous(years) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| Mean | 57.1 ± 8.66 | 54.7 ± 7.63 | 55.8 ± 7.37 | 55.9 ± 7.89 |
| Age, Customized(participants) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| <45 years | 3 | 3 | 2 | 8 |
| Between 45 and 64 years | 25 | 29 | 30 | 84 |
| ≥65 years | 7 | 3 | 3 | 13 |
| Sex: Female, Male(Participants) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| Female | 14 | 10 | 18 | 42 |
| Male | 21 | 25 | 17 | 63 |
| Race/Ethnicity, Customized(participants) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 15 | 14 | 40 |
| Non-Hispanic or Latino | 24 | 20 | 21 | 65 |
| Race/Ethnicity, Customized(participants) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 5 | 2 | 11 |
| Black or African American | 6 | 6 | 7 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| White | 25 | 23 | 26 | 74 |
| Region of Enrollment(participants) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| United States | 35 | 35 | 35 | 105 |
| Height(cm) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| Mean | 169.4 ± 9.81 | 169.8 ± 9.41 | 167.0 ± 12.30 | 168.8 ± 10.56 |
| Weight(kg) | Placebo QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|
| Mean | 93.41 ± 19.165 | 94.56 ± 20.084 | 92.33 ± 24.027 | 93.43 ± 21.012 |
10 further baseline measures are reported on the registry.
The record gives a start of Jan 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil